has been reported that a working group of Dr. Richard Vile, Mayo Clinic College of Medicine led in Rochester, Minnesota, published the results of their work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. Paper, entitled paper, entitled ‘Cyclophosphamide Facilitates Antitumor Efficacy against subcutaneous tumors after intravenous administration of reovirus ‘appears in the 1st January 2008 issue of Clinical Cancer Research Online. ‘This exciting Mayo Clinic work supported the initiation of our combination REOLYSI and cyclophosphamide clinical trial, which was recently approved by the UK health authorities,’said Dr.
Investors should the Company ‘s quarterly and annual filings with the Canadian and U.S. Securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against over-reliance The-looking statements. The company assumes no obligation to update such forward-looking statements. Click for more background information on HR ,, the State Flexibility ActOn..African Americans are more likely can be diagnosed with advanced head and and neck squamous cell carcinoma and have a worse five-year survival rate of than Caucasians. The time not know whether significant biological rather than socioeconomic disparities account to some differences in the results.